GENE ONLINE|News &
Opinion
Blog

2022-08-29| R&D

Are iPSCs safe? Nearly 75% of Skin Stem Cells Have Severe DNA Damage from UV Exposure

by Richard Chau
Share To

Stem cells are important tools in the field of regenerative medicine. In addition to their regenerative capacity, these cells can also differentiate into other types of somatic cells, among which induced pluripotent stem cell (iPSC), a new generation of technologically induced multifunctional stem cells, can be genetically modified to return differentiated cells to their pre-differentiated stem cells.

Related Article: BIO Asia-Taiwan 2022: Top iPS Cell Technologies at Affordable Prices – Keynote by Nobel Laureate Shinya Yamanaka

Despite the contribution of iPSC to stem cell applications, a recent large-scale iPSC genomic study at the University of Cambridge found that nearly 3/4 of skin-derived stem cells were found to have severe DNA damage. They theorize that this phenomenon may be due to frequent skin exposure to external UV radiation. Given the increased risk of developing cancers with the accumulation of mutations, careful selection of the source of stem cells and confirmation of safety are of great importance. The results of this study were recently published in Nature Genetics.

Severe DNA Damage Found in Nearly 75% of Skin iPSCs

In order to conduct a large-scale analysis of the genomic characteristics of human iPSCs (hiPSCs), the Cambridge University team collected a total of nearly 700 cell lines from two iPSC banks and performed a genomic comparison of subclone cells derived from these cell lines. Overall, they found that even iPSCs from the same patient were genetically damaged to varying degrees depending on the distribution of cells.

The results indicate that fibroblast-derived hiPSCs have significant DNA mutations (up to 15 mutations per megabase) and that up to 72% of skin iPSCs have severe DNA damage due to UV exposure. This is an alarming observation as the number of mutations found in these cell lines derived from skin biopsies of healthy people is even higher than that in some tumor tissues from cancer patients.

Mutations in Blood iPSCs Independent of UV Stimulation

The team also analyzed blood-derived hiPSCs and found that they had fewer mutations than fibroblast-derived hiPSCs and found no UV-related damage. However, it should be noted that about 25% of blood-derived hiPSCs have BCOR mutations, a commonly found mutation in hematological cancers, and that iPSCs with BCOR mutations tend to produce “extra-neuronal” cells during the process of differentiation. The frequency of this mutation will also accumulate even in cells without BCOR mutations during cell culture expansion.

Prof. Serena Nik-Zainal, the project leader, concluded that as stem cell applications become more widespread, the importance of whole genome sequencing of cells before treatment has become more evident. This is not only true for those working in the field of neuronal stem cell and blood stem cell research, but essentially all cell lines of iPSCs are at risk of harboring mutated genes. Thus, it would be more pragmatic to learn as much as possible about the nature and extent of DNA damage to make a safer and more reliable choice of cell lines.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
ASCO Breakthrough 2024: Radiation Alone Works as Well as Chemoradiation for Low-Risk Nasopharyngeal Cancer
2024-08-08
New Research Highlights Potential for Surgery-Free Management of Esophageal Cancer at ASCO Breakthrough 2024
2024-08-08
Wistar and Accelerated Biosciences Partner to Develop Novel hTSCs Platform for Immunotherapies
2024-07-15
LATEST
Bio Asia Pacific 2024 Close ASEAN Collaborations: Catalyzing Innovation and Global Partnerships
2024-09-12
Illumina’s IVD Biomarker Test Becomes the First FDA-approved Pan-cancer Companion Diagnostics Kit
2024-09-11
Lotus Pharma Expands in Southeast Asia with Alpha Choay Acquisition from Sanofi
2024-09-06
Indian CDMO Stocks in the Spotlight: US House to Vote on BIOSECURE Act Next Week
2024-09-06
Eli Lilly Joins Forces with AI Startup Genetic Leap in $409M Deal Centered Around RNA-Targeted Drug Discovery
2024-09-06
Illumina Wins EU Court Battle, Dodges Fine, but Grail Deal Already Void
2024-09-05
Breaking New Ground for Clinical Trials with AI/ML Applications
2024-09-05
EVENT
2024-09-13
ESMO Congress 2024
Barcelona, Spain
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
Scroll to Top